Measured Steps: Navigating the Path of Oligoprogressive Lung Cancer with Targeted and Immunotherapies

Mandy Jongbloed, Atulya A. Khosla, Valentina Bartolomeo, Karan Jatwani, Rohit Singh, Dirk K.M. De Ruysscher, Lizza E.L. Hendriks, Aakash Desai

Research output: Contribution to journalReview articlepeer-review


Abstract: Purpose of Review: This review discusses the definitions, treatment modalities, management, future directions, and ongoing clinical trials of oligoprogressive disease in oncogene-driven and non-oncogene-driven NSCLC. Recent Findings: During the last decades, diagnostic and treatment modalities for oligometastatic NSCLC have advanced significantly, leading to improved survival. Additionally, our understanding of the tumor biology of oligoprogressive disease has expanded. However, despite the efforts of organizations, such as EORTC, ESTRO, and ASTRO proposing definitions for oligometastatic and oligoprogressive disease, heterogeneity in definitions persists in (ongoing) trials. Summary: Recognizing the significance of subclassification within oligoprogressive disease in NSCLC and the varying risks associated with subsequent metastatic spread, there is a call for tailored management strategies. A consensus on standardized criteria for the definition of oligoprogressive disease is urgently needed and will not only facilitate meaningful comparisons between studies but also pave the way for the development of personalized treatment plans that take into account the heterogeneous nature of oligoprogressive disease. Graphical Abstract: [Figure not available: see fulltext.].

Original languageEnglish
JournalCurrent Oncology Reports
StateAccepted/In press - 2024
Externally publishedYes


  • Definition
  • Local radical therapy
  • Oligometastatic disease
  • Oligoprogressive disease
  • Treatment strategies


Dive into the research topics of 'Measured Steps: Navigating the Path of Oligoprogressive Lung Cancer with Targeted and Immunotherapies'. Together they form a unique fingerprint.

Cite this